Increase in HLA-G1 proteolytic shedding by tumor cells: A regulatory pathway controlled by NF-κB inducers

Cellular and Molecular Life Sciences

Volumn 63, Issue 22, 2006, Pages 2669-2681

  Zidi, I ^a   Guillard, C ^a   Marcou, C ^a   Krawice Radanne, I ^a   Sangrouber, D ^a   Rouas Freiss, N ^a   Carosella, E D ^a   Moreau, P ^a  

^a DIF   (France)

Author keywords

HLA G; PMA; Proteolytic shedding; TNF ; Tumor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METALLOPROTEINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN; PROTEIN HLA G1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEOLYTIC SHEDDING; TUMOR CELL; TUMOR CELL LINE; TUMOR ESCAPE;

CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CHORIOCARCINOMA; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; MELANOMA; NF-KAPPA B; PROTEIN MODIFICATION, TRANSLATIONAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; TETRADECANOYLPHORBOL ACETATE; TUMOR ESCAPE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751285415     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-006-6341-y     Document Type: Article

References (87)

1. Carosella, E. D., Moreau, P., Le Maoult, J., Le Discorde, M., Dausset, J. and Rouas-Freiss, N. (2003) HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv. Immunol. 81, 199-252.
2. Rouas-Freiss, N., Moreau, P., Ferrone, S. and Carosella, E. D. (2005) HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer. Res. 65, 10139-10144.
3. Bonizzi, G. and Karin, M. (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25, 280-288.
4. Karin, M. and Greten, F. R. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749-759.
5. Menier, C., Rabreau, M., Challier, J. C., Le Discorde, M., Carosella, E. D. and Rouas-Freiss, N. (2004) Erythroblasts secrete the non classical HLA-G molecule from primitive to definitive hematopoiesis. Blood 104, 3153-3160.
6. Rebmann, V., Regel, J., Stolke, D. and Grosse-Wilde, H. (2003) Secretion of sHLA-G molecules in malignancies. Semin. Cancer Biol. 13, 371-377.
7. Amiot, L., Le Friec, G., Sebti, Y., Drenou, B., Pangault, C., Guilloux, V., Leleu, X., Bernard, M., Facon, T. and Fauchet, R. (2003) HLA-G and lymphoproliferative disorders. Semin. Cancer Biol. 13, 379-385.
8. Rouas-Freiss, N., Marchal, R. E., Kirszenbaum, M., Dausset, J. and Carosella, E. D. (1997) The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc. Natl. Acad. Sci. USA 94, 5249-5254.
9. Le Gal, F. A., Riteau, B., Sedlik, C., Khalil-Daher, I., Menier, C., Dausset, J., Guillet, J. G., Carosella, E. D. and Rouas-Freiss, N. (1999) HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int. Immunol. 11, 1351-1356.
10. Fournel, S., Aguerre-Girr, M., Huc, X., Lenfant, F., Alam, A., Toubert, A., Bensussan, A. and Le Bouteiller, P. (2000) Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J. Immunol. 164, 6100-6104.
11. Riteau, B., Rouas-Freiss, N., Menier, C., Paul, P., Dausset, J. and Carosella, E. D. (2001) HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J. Immunol. 166, 5018-5026.
12. Riteau, B., Menier, C., Khalil-Daher, I., Sedlik, C., Dausset, J., Rouas-Freiss, N. and Carosella, E. D. (1999) HLA-G inhibits the allogeneic proliferative response. J. Reprod. Immunol. 43, 203-211.
13. Bainbridge, D. R., Ellis, S. A. and Sargent, I. L. (2000) HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J. Reprod. Immunol. 48, 17-26.
14. Lila, N., Rouas-Freiss, N., Dausset, J., Carpentier, A. and Carosella, E. D. (2001) Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc. Natl. Acad. Sci. USA 98, 12150-12155.
15. Le Rond, S., Le Maoult, J., Creput, C., Menier, C., Deschamps, M., Le Friec, G., Amiot, L., Durrbach, A., Dausset, J., Carosella, E. D. and Rouas-Freiss, N. (2004) Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. Eur. J. Immunol. 34, 649-660.
16. Colonna, M., Samaridis, J., Cella, M., Angman, L., Allen, R. L., O'Callaghan, C., Dunbar, R., Ogg, G. S., Cerundolo, V. and Rolink, A. (1998) Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J. Immunol. 160, 3096-3100.
17. Cosman, D., Fanger, N., Borges, L., Kubin, M., Chin, W., Peterson, L. and Hsu M.-L. (1997) A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7, 273-282.
18. Colonna, M., Navarro, F., Bellon, T., Llano, M., Garcia, P., Samaridis, J., Angman, L., Cella, M. and Lopez-Botet, M. (1997) A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 186, 1809-1818.
19. Ponte, M., Cantoni, C., Biassoni, R., Tradori-Cappai, A., Bentivoglio, G., Vitale, C., Bertone, S., Moretta, A., Moretta, L. and Mingari, M. C. (1999) Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc. Natl. Acad. Sci. USA 96, 5674-5679.
20. Rajagopalan, S. and Long, E. O. (1999) A human histocompatibility leucocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189, 1093-1099.
21. Park, G. M., Lee, S., Park, B., Kim, E., Shin, J., Cho, K. and Ahn, K. (2004) Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem. Biophys. Res. Commun. 313, 606-611.
22. Rouas-Freiss, N., Goncalves, R. M., Menier, C., Dausset, J. and Carosella, E. D. (1997) Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc. Natl. Acad. Sci. USA 94, 11520-11525.
23. Hunt, J. S., Petroff, M. G., McIntire, R. H. and Ober, C. (2005) HLA-G and immune tolerance in pregnancy. FASEB J. 19, 681-693.
24. Fuzzi, B., Rizzo, R., Criscuoli, L., Noci, I., Melchiorri, L., Scarselli, B., Bencini, E., Menicucci, A. and Baricordi, O. R. (2002) HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur. J. Immunol. 32, 311-315.
25. Sher, G., Keskintepe, L., Fisch, J. D., Acacio, B. A., Ahlering, P., Batzofin, J. and Ginsburg, M. (2005) Soluble human leukocyte antigen G expression in phase I culture media at 46 h after fertilization predicts pregnancy and implantation from day 3 embryo transfer. Fertil. Steril. 83, 1410-1413.
26. Sher, G., Keskintepe, L., Nouriani, M., Roussev, R. and Batzofin, J. (2004) Expression of sHLA-G in supernatants of individually cultured 46-h embryos: a potentially valuable indicator of 'embryo competency' and IVF outcome. Reprod. Biomed. Online. 9, 74-78.
27. Noci, I., Fuzzi, B., Rizzo, R., Melchiorri, L., Criscuoli, L., Dabizzi, S., Biagiotti, R., Pellegrini, S., Menicucci, A. and Baricordi, O. R. (2005) Embryonic soluble HLA-G as a marker of developmental potential in embryos. Hum. Reprod. 20, 138-146.
28. Yie, S. M., Balakier, H., Motamedi, G. and Librach, C. L. (2005) Secretion of human leukocyte antigen-G by human embryos is associated with a higher in vitro fertilization pregnancy rate. Fertil. Steril. 83, 30-36.
29. Hviid, T. V., Hylenius, S., Lindhard, A. and Christiansen, O. B. (2004) Association between human leukocyte antigen-G genotype and success of in vitro fertilization and pregnancy outcome. Tissue Antigens 64, 66-69.
30. Lila, N., Carpentier, A., Amrein, C., Khalil-Daher, I., Dausset, J. and Carosella, E. D. (2000) Implication of HLA-G molecule in heart-graft acceptance. Lancet 355, 2138.
31. Lila, N., Amrein, C., Guillemain, R., Chevalier, P., Latremouille, C., Fabiani, J. N., Dausset, J., Carosella, E. D. and Carpentier, A. (2002) Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 105, 1949-1954.
32. Creput, C., Durrbach, A., Charpentier, B., Carosella, E. D. and Rouas-Freiss, N. (2003) HLA-G: immunoregulatory molecule involved in allograft acceptance. Nephrologie 24, 451-456.
33. Creput, C., Durrbach, A., Menier, C., Guettier, C., Samuel, D., Dausset, J., Charpentier, B., Carosella, E. D. and Rouas-Freiss, N. (2003) Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J. Hepatol. 39, 587-594.
34. Creput, C., Le Friec, G., Bahri, R., Amiot, L., Charpentier, B., Carosella, E., Rouas-Freiss, N. and Durrbach, A. (2003) Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum. Immunol. 64, 1033-1038.
35. Paul, P., Rouas-Freiss, N., Khalil-Daher, I., Moreau, P., Riteau, B., Le Gal, F. A., Avril, M. F., Dausset, J., Guillet, J. G. and Carosella, E. D. (1998) HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA 95, 4510-4515.
36. Rouas-Freiss, N., LeMaoult, J., Moreau, P., Dausset, J. and Carosella, E. D. (2003) HLA-G in transplantation: a relevant molecule for inhibition of graft rejection? Am. J. Transplant 3, 11-16.
37. Lemaoult, J., Rouas-Freiss, N. and Carosella, E. D. (2005) Immuno-tolerogenic functions of HLA-G: relevance in transplantation and oncology. Autoimmun. Rev. 4, 503-509.
38. Huxford, T., Huang, D. B., Malek, S. and Ghosh, G. (1998) The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 95, 759-770.
39. Pahl, H. L. (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18, 6853-6866.
40. Marienfeld, R., Berberich-Siebelt, F., Berberich, I., Denk, A., Serfling, E. and Neumann, M. (2001) Signalspecific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-kappaB control. Oncogene 20, 8142-8147.
41. Osborn, L., Kunkel, S. and Nabel, G. J. (1989) Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc. Natl. Acad. Sci. USA 86, 2336-2340.
42. Karin, M. and Ben-Neriah, Y. (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18, 621-663.
43. Li, Q. and Verma, I. M. (2002) NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2, 725-734.
44. Barnes, P. J. and Karin, M. (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066-1071.
45. Doi, T. S., Takahashi, T., Taguchi, O., Azuma, T. and Obata, Y. (1997) NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J. Exp. Med. 185, 953-961.
46. Karin, M. and Lin, A. (2002) NF-kappaB at the crossroads of life and death. Nat. Immunol. 3, 221-227.
47. Sun, S. C. and Xiao, G. (2003) Deregulation of NF-kappaB and its upstream kinases in cancer. Cancer Metastasis Rev. 22, 405-422.
48. Wu, J. T. and Kral, J. G. (2005) The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J. Surg. Res. 123, 158-169.
49. Gobin, S. J., Keijsers, V., van Zutphen, M. and van den Elsen, P. J. (1998) The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J. Immunol. 161, 2276-2283.
50. Gobin, S. J. and van den Elsen, P. J. (1999) The regulation of HLA class I expression: is HLA-G the odd one out? Semin Cancer Biol 9, 55-59.
51. Solier, C., Mallet, V., Lenfant, F., Bertrand, A., Huchenq, A. and Le Bouteiller, P. (2001) HLA-G unique promoter region: functional implications. Immunogenetics 53, 617-625.
52. Rousseau, P., Masternak, K., Krawczyk, M., Reith, W., Dausset, J., Carosella, E. D. and Moreau, P. (2004) In vivo, RFX5 binds differently to the human leucocyte antigen-E, -F, and -G gene promoters and participates in HLA class I protein expression in a cell type-dependent manner. Immunology 111, 53-65.
53. Gobin, S. J. and van den Elsen, P. J. (2000) Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum. Immunol. 61, 1102-1107.
54. Menier, C., Saez, B., Horejsi, V., Martinozzi, S., Krawice-Radanne, I., Bruel, S., Le Danff, C., Reboul, M., Hilgert, I., Rabreau, M., Larrad, M. L., Pla, M., Carosella, E. D. and Rouas-Freiss, N. (2003) Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum. Immunol. 64, 315-326.
55. Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T. and Gerritsen, M. E. (1997) Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272, 21096-21103.
56. Rouas-Freiss, N., Bruel, S., Menier, C., Marcou, C., Moreau, P. and Carosella, E. D. (2005) Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis. Int. J. Cancer 117, 114-122.
57. Paul, P., Rouas-Freiss, N., Moreau, P., Adrian Cabestre, F., Menier, C., Khalil-Daher, I., Pangault, C., Onno, M., Fauchet, R., Martinez-Laso, J., Morales, P., Arnaiz-Villena, A., Giacomini, P., Natali, P. G., Frumento, G., Ferrara, G. B., McMaster, M., Fisher, S., D. S., Ferrone, S., Dausset, J. and Carosella, E. D. (2000) HLA-G, -E, -F preworkshop: tools and protocols for analysis of non classical class I genes transcription and protein expression. Hum. Immunol 61, 1177-1195.
58. Robertson, M. J., Cochran, K. J., Cameron, C., Le, J. M., Tantravahi, R. and Ritz, J. (1996) Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 24, 406-415.
59. Kundu, J. K., Shin, Y. K. and Surh, Y. J. (2006) Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-{kappa}B in mouse skin by blocking I{kappa}B kinase activity. Carcinogenesis 27, 1465-1474 .
60. Hammar, E. B., Irminger, J. C., Rickenbach, K., Parnaud, G., Ribaux, P., Bosco, D., Rouiller, D. G. and Halban, P. A. (2005) Activation of NF-kappaB by extracellular matrix is involved in spreading and glucose-stimulated insulin secretion of pancreatic beta cells. J. Biol. Chem. 280, 30630-30637.
61. Dwivedi, D. J., Pino, G., Banh, A., Nathu, Z., Howchin, D., Margetts, P., Sivak, J. G. and West-Mays, J. A. (2006) Matrix metalloproteinase inhibitors suppress transforming growth factor-beta-induced subcapsular cataract formation. Am. J. Pathol. 168, 69-79.
62. Gronning, L. M., Cederberg, A., Miura, N., Enerback, S. and Tasken, K. (2002) Insulin and TNF alpha induce expression of the forkhead transcription factor gene Foxc2 in 3T3-L1 adipocytes via PI3K and ERK 1/2-dependent pathways. Mol. Endocrinol. 16, 873-883.
63. Davies, C. C., Bem, D., Young, L. S. and Eliopoulos, A. G. (2005) NF-kappaB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells. Cell. Signal. 17, 729-738.
64. Guillard, C., Chretien, S., Pelus, A. S., Porteu, F., Muller, O., Mayeux, P. and Duprez, V. (2003) Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i)protein beta gamma-subunit-initiated pathway. J. Biol. Chem. 278, 11050-11056.
65. Rebmann, V., Lemaoult, J., Rouas-Freiss, N., Carosella, E. D. and Grosse-Wilde, H. (2005) Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen, 2004. Hum. Immunol. 66, 853-863.
66. Moreau, P., Mouillot, G., Rousseau, P., Marcou, C., Dausset, J. and Carosella, E. D. (2003) HLA-G gene repression is reversed by demethylation. Proc. Natl. Acad. Sci. USA 100, 1191-1196.
67. Ferreira, V., Tarantino, N. and Korner, M. (1998) Discrimination between RelA and RelB transcriptional regulation by a dominant negative mutant of IkappaBalpha. J. Biol. Chem. 273, 592-599.
68. Sizemore, N., Leung, S. and Stark, G. R. (1999) Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol. Cell Biol. 19, 4798-4805.
69. Vanden Berghe, W., Plaisance, S., Boone, E., De Bosscher, K., Schmitz, M. L., Fiers, W. and Haegeman, G. (1998) p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273, 3285-3290.
70. Mouillot, G., Marcou, C., Rousseau, P., Rouas-Freiss, N., Carosella, E. D. and Moreau, P. (2005) HLA-G gene activation in tumor cells involves cis-acting epigenetic changes. Int. J. Cancer 113, 928-936.
71. Gabbianelli, M., Boccoli, G., Cianetti, L., Russo, G., Testa, U. and Peschle, C. (1990) HLA expression in hemopoietic development: class I and II antigens are induced in the definitive erythroid lineage and differentially modulated by fetal liver cytokines. J. Immunol. 144, 3354-3360.
72. Kondo, S., Yin, D., Takeuchi, J., Morimura, T., Miyatake, S. I., Nakatsu, S., Oda, Y. and Kikuchi, H. (1994) Tumour necrosis factor-alpha induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis. Br. J. Cancer 69, 627-632.
73. Moreau, P., Adrian-Cabestre, F., Menier, C., Guiard, V., Gourand, L., Dausset, J., Carosella, E. D. and Paul, P. (1999) IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int. Immunol. 11, 803-811.
74. Bhattacharyya, S., Sen, P., Wallet, M., Long, B., Baldwin, A. S. Jr and Tisch, R. (2004) Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood 104, 1100-1109.
75. Varfolomeev, E. E. and Ashkenazi, A. (2004) Tumor necrosis factor: an apoptosis JuNKie? Cell 116, 491-497.
76. Gonzalez-Hernandez, A., Lemaoult, J., Lopez, A., Alegre, E., Caumartin, J., Le Rond, S., Daouya, M., Moreau, P. and Carosella, E. D. (2005) Linking two immuno-suppressive molecules: indoleamine 2,3 dioxygenase can modify HLA-G cell-surface expression. Biol. Reprod. 73, 571-578.
77. Gobin, S. J., Biesta, P. and Van den Elsen, P. J. (2003) Regulation of human beta 2-microglobulin transactivation in hematopoietic cells. Blood 101, 3058-3064.
78. Pai, S., O'Sullivan, B. J., Cooper, L., Thomas, R. and Khanna, R. (2002) RelB nuclear translocation mediated by C-terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells. J. Virol. 76, 1914-1921.
79. Huang, S. C., Ho, C. T., Lin-Shiau, S. Y. and Lin, J. K. (2005) Carnosol inhibits the invasion of B16/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappa B and c-Jun. Biochem. Pharmacol. 69, 221-232.
80. Sato, H., Kita, M. and Seiki, M. (1993) v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements: a mechanism regulating gene expression independent of that by inflammatory cytokines. J. Biol. Chem. 268, 23460-23468.
81. Demaria, S., Schwab, R., Gottesman, S. R. and Bushkin, Y. (1994) Soluble beta 2-microglobulin-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. J. Biol. Chem. 269, 6689-6694.
82. Powell, D. J., Hajduch, E., Kular, G. and Hundal, H. S. (2003) Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKC-zeta-dependent mechanism. Mol. Cell Biol. 23, 7794-7808.
83. Szlosarek, P. W. and Balkwill, F. R. (2003) Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 4, 565-573.
84. Mantovani, G., Maccio, A., Mura, L., Massa, E., Mudu, M. C., Mulas, C., Lusso, M. R., Madeddu, C. and Dessi, A. (2000) Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J. Mol. Med. 78, 554-561.
85. Sebti, Y., Le Friec, G., Pangault, C., Gros, F., Drenou, B., Guilloux, V., Bernard, M., Lamy, T., Fauchet, R. and Amiot, L. (2003) Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum. Immunol. 64, 1093-1101.
86. Nuckel, H., Rebmann, V., Durig, J., Duhrsen, U. and Grosse-Wilde, H. (2005) HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105, 1694-1698.
87. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S. and Kuliopulos, A. (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313.